Article info

PDF
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies
  1. Dr J Honnorat, Neurologie B, Hôpital Neurologique de Lyon, 59 boulevard Pinel, 69677 Bron Cedex, France; jerome.honnorat{at}chu-lyon.fr
View Full Text

Citation

Honnorat J, Cartalat-Carel S, Ricard D, et al
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies

Publication history

  • Received October 24, 2007
  • Revised June 25, 2008
  • Accepted August 8, 2008
  • First published October 17, 2008.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.